Teicoplanin

Teicoplanin is a real glycopeptide antibiotic, approved across Europe, Japan and elsewhere since 1988 as a close cousin of vancomycin — with Cochrane-reviewed evidence that it's just as effective and meaningfully less likely to damage the kidneys, yet an FDA advisory committee reviewed it in the early 1990s and it has still never been approved in the US.

A close cousin of vancomycin

Teicoplanin is a glycopeptide antibiotic, structurally and mechanistically close to vancomycin already covered on this site — both bind the D-alanyl-D-alanine terminus of bacterial cell-wall precursors, blocking the cross-linking reactions that build the wall. It was first isolated in 1978 by researchers at the Lepetit Research Center in Italy, from a soil actinomycete (Actinoplanes teichomyceticus) found in an Indian soil sample, and reached clinical use in Europe in 1988 for serious gram-positive infections — the same category vancomycin treats, but a genuinely distinct molecule with its own pharmacokinetics.

The Cochrane-level evidence: equally effective, meaningfully safer

A Cochrane systematic review pooling 24 trials and 2,610 patients (Cavalcanti et al., Cochrane Database Syst Rev 2010;(6):CD007022) found teicoplanin and vancomycin equally effective — similar clinical cure (RR 1.03), microbiological cure (RR 0.98) and mortality (RR 1.02) — but teicoplanin reduced the risk of nephrotoxicity (RR 0.66, 95% CI 0.48-0.90), along with lower rates of skin rash (RR 0.57), red man syndrome (RR 0.21) and total adverse events (RR 0.73). Its longer half-life also supports once-daily dosing, including by intramuscular injection — something vancomycin's own pharmacokinetics don't allow — making teicoplanin a genuinely more convenient option for outpatient parenteral antibiotic therapy in patients without easy venous access.

The FDA review that never became an approval

None of that evidence base ever produced a US approval. Marion Merrell Dow submitted a New Drug Application for teicoplanin (as Targocid) to the FDA in March 1991, and the agency's Anti-Infective Drugs Advisory Committee reviewed the submission in closed session, requesting additional clinical data. What became of that specific application afterward isn't something we could confirm from public records — but the practical outcome is unambiguous: more than three decades after its European launch, teicoplanin still has no FDA approval, while it has remained continuously marketed across the EU, UK, Japan and elsewhere the entire time.

A retrospective COVID-19 signal worth flagging, and treating cautiously

A real, if preliminary, side story: teicoplanin was studied early in the pandemic as a repurposed COVID-19 treatment, based on laboratory evidence that it inhibits cathepsin L, an enzyme some coronaviruses need to enter human cells. One 2021 retrospective comparison in 115 hospitalized patients found a significantly lower mortality rate with teicoplanin added to standard care than with standard care alone (1.9% vs. 14.8%, p<.05) (Yasar et al., Int J Clin Pract 2021;75:e14752, PMID 34431178). That's a real, published result — and also a small, single-center, non-randomized one, exactly the kind of signal this site treats as worth watching rather than proof of anything. No randomized trial confirming a COVID-19 benefit was found, and teicoplanin has no approval anywhere for that use.

Current status

Teicoplanin remains in active clinical use across Europe, Japan and much of the rest of the world for serious gram-positive infections, including MRSA bacteremia and endocarditis — typically reached for as a genuine alternative to vancomycin specifically when kidney function is a concern. It has no US availability and no wellness or grey-market presence: a hospital-administered antibiotic, not a substance sold to individuals.